This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jan 26;381(9863):273-5.

doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

Evaluation of regorafenib in colorectal cancer and GIST

Tom Waddell¹, David Cunningham

Affiliations

PMID: 23177516
DOI: 10.1016/S0140-6736(12)62006-6

Comment

Evaluation of regorafenib in colorectal cancer and GIST

Tom Waddell et al. Lancet. 2013.

. 2013 Jan 26;381(9863):273-5.

doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22.

Authors

Tom Waddell¹, David Cunningham

Affiliation

¹ Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK.

PMID: 23177516
DOI: 10.1016/S0140-6736(12)62006-6

No abstract available

PubMed Disclaimer

Comment on

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Grothey A, et al. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177514 Clinical Trial.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.

Similar articles

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
[No authors listed] [No authors listed] Oncology (Williston Park). 2012 Nov;26(11):1072. Oncology (Williston Park). 2012. PMID: 23330348 No abstract available.
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L. Wu L, et al. Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25378911 Free PMC article.
Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Lyseng-Williamson KA. Lyseng-Williamson KA. BioDrugs. 2013 Oct;27(5):525-31. doi: 10.1007/s40259-013-0061-2. BioDrugs. 2013. PMID: 23975637 Review.
[Consensus on the medical treatment of gastrointestinal stromal tumors].
[No authors listed] [No authors listed] Zhonghua Zhong Liu Za Zhi. 2007 Nov;29(11):875-7. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 18396652 Chinese. No abstract available.

See all similar articles

Cited by

Management of regorafenib-related toxicities: a review.
Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW. Krishnamoorthy SK, et al. Therap Adv Gastroenterol. 2015 Sep;8(5):285-97. doi: 10.1177/1756283X15580743. Therap Adv Gastroenterol. 2015. PMID: 26327919 Free PMC article. Review.
Critical appraisal of the use of regorafenib in the management of colorectal cancer.
Festino L, Fabozzi A, Manzo A, Gambardella V, Martinelli E, Troiani T, De Vita F, Orditura M, Ciardiello F, Morgillo F. Festino L, et al. Cancer Manag Res. 2013 Apr 12;5:49-55. doi: 10.2147/CMAR.S34281. Print 2013. Cancer Manag Res. 2013. PMID: 23610528 Free PMC article.
Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.
Jitawatanarat P, Wee W. Jitawatanarat P, et al. J Gastrointest Oncol. 2013 Jun;4(2):231-8. doi: 10.3978/j.issn.2078-6891.2013.008. J Gastrointest Oncol. 2013. PMID: 23730520 Free PMC article.
Targeted Nanoparticles: the Smart Way for the Treatment of Colorectal Cancer.
Abdellatif AAH, Alshubrumi AS, Younis MA. Abdellatif AAH, et al. AAPS PharmSciTech. 2024 Jan 24;25(1):23. doi: 10.1208/s12249-024-02734-9. AAPS PharmSciTech. 2024. PMID: 38267656 Review.
Advances in 3D Vascularized Tumor-on-a-Chip Technology.
Jung S, Jo H, Hyung S, Jeon NL. Jung S, et al. Adv Exp Med Biol. 2022;1379:231-256. doi: 10.1007/978-3-031-04039-9_9. Adv Exp Med Biol. 2022. PMID: 35760994

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information